ClinicalTrials.gg
CompletedNCT00037050Updated Sep 14, 2009

Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria

A Phase 3 interventional study of Linezolid and Vancomycin in Bacterial Infections, Gram-Positive Bacterial Infections and Bacteremia, sponsored by Pfizer. Completed. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2009-09-14.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
739
Allocation
Randomized
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Bacterial Infections by Pfizer — none open to participants now, none under way, none of them phase 3. Bacterial Infections · Pfizer.

Enrollment
4th of 21
739 · median 134
Started
2002
with 3 others
Phase 3
9 of 28
none open now
Registered
4th of 28
by date

Among the 28 studies in Bacterial Infections by Pfizer, this one is the 4th largest by enrollment of the 21 interventional ones that give a count, is one of 4 that started in 2002, is one of 9 in phase 3, and was the 4th registered.

Bacterial Infections

585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

None of the 28 studies in Bacterial Infections by Pfizer is open now. The open studies under Bacterial Infections, anywhere →

Who these studies take

Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.

This study: 13 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies in Bacterial Infections by Pfizer as a file.
02

Study summary

This study will treat patients who have a short term central catheter that is thought to be infected with a specific bacteria (gram positive bacteria)

03

Conditions studied

  • Bacterial Infections
  • Gram-Positive Bacterial Infections
  • Bacteremia
04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a central indwelling catheter with signs and symptoms of infection

Exclusion criteria

Exclusion Criteria:

  • Patients with tunneled catheter which cannot be removed.
  • Patients with evidence of endovascular infection including endocarditis.
  • Patients with infection of permanent intravascular devices.
  • Patients who have received more than 1 day of another antibiotic before enrollment.
  • Patients with and low .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
739 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. The empiric treatment of patients with complicated skin and skin structure infections (cSSSI) related to an indwelling catheter;

  2. The empiric treatment of patients with gram-positive catheter-related bloodstream infections.

Secondary outcomes

  1. Clinical efficacy of linezolid compared to vancomycin/oxacillin/dicloxacillin.2.Incidence of late metastatic sequelae associated with S. aureus infections in patients treated with linezolid

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2002 and a completion of Jul 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2002
First posted
May 15, 2002
Start
Apr 2002
CompletionActual
Jul 2005
Last update
Sep 14, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00037050
Lead sponsor
Pfizer
First posted
May 15, 2002
Start date
Apr 2002
Completion
Jul 2005
Last update
Sep 14, 2009

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Linezolid · Vancomycin · Dicloxacillin

Start the discussion